Global Glaucoma Drug Forecast and Market Analysis Report 2022-2030 - Development of Drugs with Novel MOA or Administration Marks a Shift in Glaucoma Corporate Strategy - ResearchAndMarkets.com
Retrieved on:
Wednesday, March 9, 2022
Health, Pharmaceutical, Retinal ganglion cell, Industry, Axon, BB gun, Therapy, Severe cognitive impairment, LRRK2, Particularly dangerous situation, Field line, Prognosis, AAS, PGAS, Risk, Intraocular pressure, Cholinergic, RKI-1447, AAA, FDC, RGC Resources, Disease, IOP, CAGR, Optic nerve, Carbonic anhydrase inhibitor, Compliance, RNA, Review, Pharmaceutical industry, Medical device, Glaucoma
The "Glaucoma - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
Key Points:
- The "Glaucoma - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
- The glaucoma market is expected to grow from $2.85B in 2020 to $3.48B in 2030, a CAGR of 2%.
- The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis.
- Analysis of the current and future market competition in the global glaucoma therapeutic market.